The Sofia Influenza A+B FIA employs immunofluorescence to detect influenza B viral nucleoprotein antigens in direct nasal swab, nasopharyngeal swab, and nasopharyngeal aspirate/wash specimens and nasopharyngeal swab and nasopharyngeal aspirate/wash specimens in transport media from symptomatic patients. This qualitative test is intended for use as an aid in the rapid differential diagnosis of acute influenza B viral infections. The test is not intended to detect influenza C antigens. A negative test is recommended these results be confirmed by viral culture or an FDA-cleared influenza A and B molecular assay. Negative results do not preclude influenza virus infections and should not be used as the sole basis for treatment or other patient management decisions. This test is intended for professional and laboratory use.

The Sofia Influenza A+B FIA may be used with Sofia or Sofia 2.

Performance characteristics for influenza A and B were established during February through March 2011 when influenza viruses A/California 7/2009 (2009 H1N1), A/Perth/16/2009 (H3N2), and B/Brisbane/60/2008 (Victoria-Like) were the predominant influenza viruses in circulation according to the Mortality Weekly Report from the CDC entitled "Update: Influenza Activity--United States, 2010-2011 Season, and Composition of the 2011-2012 Influenza Vaccine." Performance characteristics may vary against other emerging influenza viruses.

If infection with a novel influenza virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, samples should be collected with appropriate infection sor novel virulent influenza viruses and sent to state or local health department for testing. Viral culture should not be attempted in these cases unless a BSL 3+ facility is available to receive and culture samples.

Device Description

The Sofia Influenza A+B FIA employs immunofluorescence technology that is used with Sofia and Sofia 2 to detect influenza virus nucleoproteins. This test allows for the differential detection of influenza A and influenza B antigens.

The patient sample is placed in the Reagent Tube, during which time the virus particles in the sample are disrupted, exposing internal viral nucleoproteins. After disruption, the sample is dispensed into the Test Cassette sample well. From the sample migrates through a test strip containing various unique chemical environments. If influenza viral antigen is present, they will be trapped in a specific location.

Note: Depending upon the user's choice, the Test Cassette is either placed inside of Sofia or Sofia 2 for automatically timed development (WALK AWAY Mode) or placed on the counter or bench top for a manually timed development and then placed into Sofia 2 to be scanned (READ NOW Mode).

Sofia and Sofia 2 will scan the test strip and measure the fluorescent signal by processing the results using method-specific algorithms. Sofia and Sofia 2 will display the test results (Positive, or Invalid) on the screen. The results can also be automatically printed on an integrated printer if this option is selected.

Sofia 2 is a microprocessor-controlled device about the size of a desk top telephone and weighs less than 3 pounds. Sofia 2 uses a fluorescent tag that is illuminated by an Ultraviolet (UV) light source to generate specific results.

AI/ML Overview

The provided text describes the 510(k) premarket notification for the "Sofia® Influenza A+B FIA on Sofia 2" device. Here's an analysis of the acceptance criteria and the study information:

1. Table of Acceptance Criteria and Reported Device Performance:

The document does not explicitly state acceptance criteria in a quantitative, objective manner (e.g., "sensitivity must be >95%"). Instead, the performance studies aim to demonstrate equivalence to the predicate device (Sofia® Influenza A+B FIA on Sofia). Therefore, the "reported device performance" is framed as proving this equivalence.

Performance Characteristic	Acceptance Criteria (Implicit: Equivalent to Predicate)	Reported Device Performance
Limit of Detection (LoD)	LoD on Sofia 2 equivalent to LoD on Sofia	Confirmed equivalent
Precision	Sofia 2 generated equivalent qualitative results to Sofia for negative and positive concentrations near positivity threshold, across multiple operators, device lots, and days.	Confirmed equivalent
Assay Development Time (Read Now mode)	Development time of 15-30 minutes is acceptable	Confirmed 15-30 minutes acceptable
Early Read (Walk Away mode)	Positive samples can be interpreted as positive as early as 3 minutes (depending on viral load)	Confirmed positive results as early as 3 minutes
Method Comparison	Comparable performance between Sofia 2 and Sofia using a panel of clinical samples	Demonstrated comparable performance
Reproducibility	Intra- and inter-operator reproducibility and intra- and inter-laboratory reproducibility, with comparable performance between Sofia 2 and Sofia.	Demonstrated successful reproducibility and comparable performance

2. Sample Size Used for the Test Set and Data Provenance:

The document mentions a "panel of clinical samples" for the Method Comparison study but does not specify the sample size for this test set nor the specific number of samples used for other studies like LoD, Precision, Early Read, or Reproducibility.

The data provenance is described as:

"Performance characteristics for influenza A and B were established during February through March 2011"
Location: Implied to be United States, as it references the "Morbidity and Mortality Weekly Report from the CDC entitled 'Update: Influenza Activity—United States, 2010-2011 Season'".
Retrospective/Prospective: The collection period (Feb-Mar 2011) and subsequent analysis suggest the data might be retrospective (collected on previously circulating strains and then tested with the devices).

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts:

The document does not provide information on the number of experts or their qualifications for establishing ground truth for the test set.

4. Adjudication Method for the Test Set:

The document does not explicitly describe an adjudication method (e.g., 2+1, 3+1). It states "viral culture or an FDA-cleared influenza A and B molecular assay" as confirmation methods for negative results, implying these are the primary methods for ground truth, rather than expert adjudication of the Sofia results themselves.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

This device is not an AI/CAD-based system designed to assist human readers. It is an in vitro diagnostic (IVD) device that provides automated results (Positive, Negative, Invalid). Therefore, an MRMC comparative effectiveness study involving human readers and AI assistance is not applicable and was not done. The system reports a direct result, not an interpretation for human review.

6. If a Standalone (i.e. algorithm only without human-in-the-loop performance) was done:

Yes, the studies conducted demonstrate standalone performance of the Sofia 2 device. The device outputs "Positive, Negative, or Invalid" results based on its internal algorithms and fluorescent signal detection, without human interpretation of the signal. The "Method Comparison" study compares the device's performance against the predicate device using clinical samples, effectively evaluating its standalone accuracy.

7. The Type of Ground Truth Used (expert consensus, pathology, outcomes data, etc):

The ground truth for defining influenza positive/negative status is indicated implicitly by these statements:

"A negative test is presumptive and it is recommended these results be confirmed by viral culture or an FDA-cleared influenza A and B molecular assay."
This suggests that viral culture and/or FDA-cleared molecular assays (which are highly sensitive and specific) were used as the reference standard or "ground truth" to determine the true influenza status of the clinical samples during the performance characteristic studies.

8. The Sample Size for the Training Set:

The document does not specify a sample size for a training set. This type of device (immunofluorescence detection with pre-defined algorithms) typically doesn't involve a "training set" in the machine learning sense. The algorithms are likely developed and validated on internal data during product development, but this information is not provided here. The studies described are primarily for verification and validation against the predicate and established performance characteristics.

9. How the Ground Truth for the Training Set was Established:

As mentioned above, a "training set" in the context of machine learning is not applicable here. For the development and initial validation of the device's algorithms, the ground truth would have likely been established using well-characterized samples (e.g., confirmed by viral culture or PCR) to tune the device's sensitivity thresholds for fluorescent signal detection. However, details on this process are not provided in this regulatory submission summary.

Summary

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized caduceus symbol, which is a staff with two snakes coiled around it, and the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged in a circular pattern around the symbol. The caduceus is a common symbol associated with healthcare and medicine. The logo is simple and recognizable, and it is used to represent the U.S. Department of Health & Human Services.

Public Health Service

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

April 14, 2017

Quidel Corporation Jennifer S. Rial Director, Regulatory Affairs 12544 High Bluff Drive, Suite 200 San Diego CA 92130

Re: K162438

Trade/Device Name: Sofia® Influenza A+B FIA on Sofia 2 Regulation Number: 21 CFR 866.3328 Regulation Name: Influenza virus antigen detection test systems Regulatory Class: II Product Code: PSZ Dated: March 13, 2017 Received: March 14, 2017

Dear Ms. Rial:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21. Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{1}------------------------------------------------

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Steven R. Gitterman -S

Uwe Scherf Director Division of Microbiology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K162438

Device Name Sofia® Influenza A+B FIA on Sofia 2

Indications for Use (Describe)

The Sofia Influenza A+B FIA may be used with Sofia or Sofia 2.

Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)	Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

Image /page/3/Picture/0 description: The image shows the logo for QuidelOrtho Corporation. The logo features a square shape with rounded corners, divided into two sections. The top section is a gradient of colors, including red, orange, yellow, green, blue, and purple. The bottom section is a smaller square filled with a blue and purple gradient. Below the square is the word "QUIDEL" in a modern, sans-serif font.

5. 510(K) SUMMARY

{4}------------------------------------------------

Image /page/4/Picture/0 description: The image shows the logo for QuidelOrtho Corporation. The logo features a square shape with a smaller square cut out of the lower right corner. The larger square is filled with a gradient of colors, including red, orange, yellow, green, blue, and purple. The word "QUIDEL" is written in a sans-serif font below the square.

5.1. Submitter

Quidel Corporation 12544 High Bluff Drive, Suite 200 San Diego, California 92130 Telephone: 858-552-7910 Fax: 858-646-8045

5.2. Submission Contact

Jennifer S. Rial

5.3. Date Prepared

August 26, 2016

5.4. Proprietary and Established Names

Sofia® Influenza A+B FIA on Sofia 2

5.5. Common Name

Same as above

5.6. Regulatory Information

Product Code / Name	Class	Regulatory Section	Panel
PSZ - Devices detecting influenza a, b, and c virus antigens	II	21 CFR 866.3328	Microbiology
KHO - Fluorometer for clinical use

5.7. Predicate Device

Sofia® Influenza A+B FIA on Sofia (K153012, K131606, and K112177)

5.8. Device Description

{5}------------------------------------------------

Image /page/5/Picture/0 description: The image features the logo of QuidelOrtho Corporation. The logo consists of a stylized square divided into two sections. The larger section is a gradient of colors, including yellow, orange, red, purple, blue, and green. The smaller section is a darker shade of blue. Below the square is the word "QUIDEL" in a sans-serif font.

5.9. Intended Use

The Sofia Influenza A+B FIA employs immunofluorescence to detect influenza A and influenza B viral nucleoprotein antigens in direct nasal swab, nasopharyngeal swab, and nasopharyngeal aspirate/wash specimens and nasopharyngeal swab and nasopharyngeal aspirate/wash specimens in transport media from symptomatic patients. This qualitative test is intended for use as an aid in the rapid differential diagnosis of acute influenza A and influenza B viral infections. The test is not intended to detect influenza C antigens. A negative test is presumptive and it is recommended these results be confirmed by viral culture or an FDA-cleared influenza A and B molecular assay. Negative results do not preclude influenza virus infections and should not be used as the sole basis for treatment or other patient management decisions. This test is intended for professional and laboratory use.

The Sofia Influenza A+B FIA may be used with Sofia or Sofia 2.

Performance characteristics for influenza A and B were established during February through March 2011 when influenza viruses A/California/7/2009 (2009 H1N1), A/Perth/16/2009 (H3N2), and B/Brisbane/60/2008 (Victoria-Like) were the predominant influenza viruses in circulation according to the Morbidity and Mortality Weekly Report from the CDC entitled "Update: Influenza Activity--United States, 2010-2011 Season, and Composition of the 2011-2012 Influenza Vaccine." Performance characteristics may vary against other emerging influenza viruses.

If infection with a novel influenza virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, samples should be collected with appropriate infection control precautions for novel virulent influenza viruses and sent to state or local health department for testing. Viral culture should not be attempted in these cases unless a BSL 3+ facility is available to receive and culture samples.

{6}------------------------------------------------

Image /page/6/Picture/0 description: The image shows the logo for QuidelOrtho Corporation. The logo features a square shape with rounded corners, filled with a gradient of colors resembling a rainbow. A smaller square is cut out from the lower right corner of the larger square. Below the square is the word "QUIDEL" in a stylized, sans-serif font.

Substantial Equivalence Information: 5.10

1. Predicate Device Name: Sofia Influenza A+B FIA on Sofia
1. Predicate 510(k) Numbers: K153012, K131606, and K112177
1. Comparison with Predicate:

Similarities and Differences
Item	Sofia Influenza A+B FIA on Sofia	Sofia 2 Influenza A+B FIA on Sofia and Sofia 2
Intended Use	The Sofia Influenza A+B FIA employsimmunofluorescence to detect influenza A andinfluenza B viral nucleoprotein antigens in nasalswab, nasopharyngeal swab, and nasopharyngealaspirate/wash in fresh or transport mediaspecimens from symptomatic patients. Thisqualitative test is intended for use as an aid in therapid differential diagnosis of acute influenza Aand influenza B viral infections. The test is notintended to detect influenza C antigens. A negativetest is presumptive and it is recommended theseresults be confirmed by viral culture or an FDA-cleared influenza A and B molecular assay.Negative results do not preclude influenza virusinfections and should not be used as the sole basisfor treatment or other patient managementdecisions. This test is intended for professional andlaboratory use.Performance characteristics for influenza A and Bwere established during February through March2011 when influenza viruses A/California/7/2009(2009 H1N1), A/Perth/16/2009 (H3N2),andB/Brisbane/60/2008 (Victoria-Like) werethepredominant influenza viruses in circulationaccording to the Morbidity and Mortality WeeklyReport from the CDC entitled "Update: InfluenzaActivity--United States, 2010-2011 Season, andComposition of the 2011-2012 Influenza Vaccine."Performance characteristics may vary against otheremerging influenza viruses.If infection with a novel influenza virus issuspectedbasedoncurrentclinicalandepidemiological screening criteria recommendedby public health authorities, samples should becollectedwith appropriate infection controlprecautions for novel virulent influenza virusesand sent to state or local health department fortesting. Viral culture should not be attempted inthese cases unless a BSL 3+ facility is available toreceive and culture samples.	The Sofia Influenza A+B FIA employsimmunofluorescence to detect influenza A andinfluenza B viral nucleoprotein antigens in directnasal swab, nasopharyngeal swab, andnasopharyngeal aspirate/wash specimens andnasopharyngeal swab and nasopharyngealaspirate/wash specimens in transport media fromsymptomatic patients. This qualitative test isintended for use as an aid in the rapid differentialdiagnosis of acute influenza A and influenza Bviral infections. The test is not intended to detectinfluenza C antigens. A negative test ispresumptive and it is recommended these results beconfirmed by viral culture or an FDA-clearedinfluenza A and B molecular assay. Negativeresults do not preclude influenza virus infectionsand should not be used as the sole basis fortreatment or other patient management decisions.This test is intended for professional and laboratoryuse.The Sofia Influenza A+B FIA may be used withSofia or Sofia 2.Performance characteristics for influenza A and Bwere established during February through March2011 when influenza viruses A/California/7/2009(2009 H1N1), A/Perth/16/2009 (H3N2),andB/Brisbane/60/2008 (Victoria-Like)werethepredominant influenza viruses in circulationaccording to the Morbidity and Mortality WeeklyReport from the CDC entitled "Update: InfluenzaActivity--United States, 2010-2011 Season, andComposition of the 2011-2012 Influenza Vaccine.'"Performance characteristics may vary against otheremerging influenza viruses.If infection with a novel influenza virus issuspected based on current clinical andepidemiological screening criteria recommendedby public health authorities, samples should becollected with appropriate infection controlprecautions for novel virulent influenza viruses andsent to state or local health department for testing.Viral culture should not be attempted in these casesunless a BSL 3+ facility is available to receive andculture samples.
Similarities and Differences
Item	Sofia Influenza A+B FIA on Sofia	Sofia 2 Influenza A+B FIA on Sofia and Sofia 2
Calibration Check	Calibration Check required every 30 days or less,as set by the supervisor. A special CalibrationCassette is provided with the Installation Pack.	Same and uses the same Calibration Cassette
Development Modes	Two basic assay development modes:Walk-Away: User can walk away during theassay cassette development periodRead Now: User manually times the assay•cassette development period outside of Sofia,then places cassette in Sofia to image andprovide test result.	Same
Development Time	15 minutes for Sofia Influenza A+B FIA	Potential for early read in Walk-Away Mode.Sofia 2 will image cassette at 3, 5, 8, 10, and 15minutes until a positive result is received.
System Components
User interface	3.5 inch diagonal color LCD display and numerickeypad with function specific buttons	4 inch color LCD touchscreen display
User Types	Has 2 distinct security levels; user and supervisorplus a Quidel only service level	Same
Barcodescanner(sample)	External hand held barcode scanner	Integrated barcode scanner but same functionality
Barcodescanner(cassette)	Integrated barcode scanner	Same using custom integrated 0.3 MP camera
Assay / instrumentinterface	Drawer (electro-mechanical)	Same (manual)
Determine test type	Instrument scans barcode on cassette	Same
Power Supply	100 - 240 VAC, self-switching, or with 4 AAbatteries	100 - 240 VAC, self-switching, or withrechargeable lithium polymer battery
Printer	Integrated printer	External printer connected via USB port (DYMOLabelWriter 450 Printer supported), optionalnetwork printer.
Dimensions	24 cm deep x 16 cm wide x 10 cm high	19.7 cm deep x 11.4 cm wide x 12.7 cm high
Weight	3 lbs	∼2.5 lbs

{7}------------------------------------------------

Image /page/7/Picture/0 description: The image shows the logo for QuidelOrtho Corporation. The logo features a square with a gradient of colors, including yellow, orange, red, purple, blue, and green. Below the square is the word "QUIDEL" in a simple, sans-serif font.

{8}------------------------------------------------

Image /page/8/Picture/0 description: The image features the logo for Quidel. The logo consists of a square shape with rounded corners, divided into four quadrants. The top and left quadrants are filled with a gradient of colors, including yellow, orange, red, and purple. The bottom right quadrant is filled with a blue color. Below the square shape, the word "QUIDEL" is written in a sans-serif font.

5.11. Performance Data

Numerous studies were undertaken to document the performance characteristics of Sofia 2 and the Sofia Influenza A+B assay, as well as to compare the performance between Sofia and Sofia 2. The studies included the following:

Limit of Detection (LoD) a.
This study confirmed that the LoD generated for the Sofia Influenza A+B FIA on Sofia 2 is equivalent to the LoD generated on Sofia.
b. Precision
This study confirmed that Sofia and Sofia 2 generated equivalent qualitative results when used by multiple operators to test negative and positive concentrations that are close to the positivity threshold, on multiple device lots, and operated over multiple days.
Assay development time C.
This study confirmed that when running Sofia 2 in Read Now mode, a development time of fifteen (15) to thirty (30) minutes is acceptable.
d. Early Read
This study confirmed that when running Sofia 2 in Walk Away mode, positive samples (depending on the viral load) can be interpreted as positive as early as 3 minutes.
Method Comparison e.
This study demonstrated that Sofia and Sofia 2 have comparable performance when using a panel of clinical samples.
f. Reproducibility
This study demonstrated intra- and inter-operator reproducibility and intra- and interlaboratory reproducibility with a panel of test samples at various influenza concentrations. This study also demonstrated comparable performance between Sofia and Sofia 2.

5.12. Conclusion

These studies demonstrated equivalent performance of the Sofia Influenza A+B FIA on the Sofia and Sofia 2 analyzers.

Regulation Number and Section

§ 866.3328 Influenza virus antigen detection test system.

(a)
Identification. An influenza virus antigen detection test system is a device intended for the qualitative detection of influenza viral antigens directly from clinical specimens in patients with signs and symptoms of respiratory infection. The test aids in the diagnosis of influenza infection and provides epidemiological information on influenza. Due to the propensity of the virus to mutate, new strains emerge over time which may potentially affect the performance of these devices. Because influenza is highly contagious and may lead to an acute respiratory tract infection causing severe illness and even death, the accuracy of these devices has serious public health implications.(b)
Classification. Class II (special controls). The special controls for this device are:(1) The device's sensitivity and specificity performance characteristics or positive percent agreement and negative percent agreement, for each specimen type claimed in the intended use of the device, must meet one of the following two minimum clinical performance criteria:
(i) For devices evaluated as compared to an FDA-cleared nucleic acid based-test or other currently appropriate and FDA accepted comparator method other than correctly performed viral culture method:
(A) The positive percent agreement estimate for the device when testing for influenza A and influenza B must be at the point estimate of at least 80 percent with a lower bound of the 95 percent confidence interval that is greater than or equal to 70 percent.
(B) The negative percent agreement estimate for the device when testing for influenza A and influenza B must be at the point estimate of at least 95 percent with a lower bound of the 95 percent confidence interval that is greater than or equal to 90 percent.
(ii) For devices evaluated as compared to correctly performed viral culture method as the comparator method:
(A) The sensitivity estimate for the device when testing for influenza A must be at the point estimate of at least 90 percent with a lower bound of the 95 percent confidence interval that is greater than or equal to 80 percent. The sensitivity estimate for the device when testing for influenza B must be at the point estimate of at least 80 percent with a lower bound of the 95 percent confidence interval that is greater than or equal to 70 percent.
(B) The specificity estimate for the device when testing for influenza A and influenza B must be at the point estimate of at least 95 percent with a lower bound of the 95 percent confidence interval that is greater than or equal to 90 percent.
(2) When performing testing to demonstrate the device meets the requirements in paragraph (b)(1) of this section, a currently appropriate and FDA accepted comparator method must be used to establish assay performance in clinical studies.
(3) Annual analytical reactivity testing of the device must be performed with contemporary influenza strains. This annual analytical reactivity testing must meet the following criteria:
(i) The appropriate strains to be tested will be identified by FDA in consultation with the Centers for Disease Control and Prevention (CDC) and sourced from CDC or an FDA-designated source. If the annual strains are not available from CDC, FDA will identify an alternative source for obtaining the requisite strains.
(ii) The testing must be conducted according to a standardized protocol considered and determined by FDA to be acceptable and appropriate.
(iii) By July 31 of each calendar year, the results of the last 3 years of annual analytical reactivity testing must be included as part of the device's labeling. If a device has not been on the market long enough for 3 years of annual analytical reactivity testing to have been conducted since the device received marketing authorization from FDA, then the results of every annual analytical reactivity testing since the device received marketing authorization from FDA must be included. The results must be presented as part of the device's labeling in a tabular format, which includes the detailed information for each virus tested as described in the certificate of authentication, either by:
(A) Placing the results directly in the device's § 809.10(b) of this chapter compliant labeling that physically accompanies the device in a separate section of the labeling where the analytical reactivity testing data can be found; or
(B) In the device's label or in other labeling that physically accompanies the device, prominently providing a hyperlink to the manufacturer's public Web site where the analytical reactivity testing data can be found. The manufacturer's home page, as well as the primary part of the manufacturer's Web site that discusses the device, must provide a prominently placed hyperlink to the Web page containing this information and must allow unrestricted viewing access.
(4) If one of the actions listed at section 564(b)(1)(A)-(D) of the Federal Food, Drug, and Cosmetic Act occurs with respect to an influenza viral strain, or if the Secretary of Health and Human Services (HHS) determines, under section 319(a) of the Public Health Service Act, that a disease or disorder presents a public health emergency, or that a public health emergency otherwise exists, with respect to an influenza viral strain:
(i) Within 30 days from the date that FDA notifies manufacturers that characterized viral samples are available for test evaluation, the manufacturer must have testing performed on the device with those viral samples in accordance with a standardized protocol considered and determined by FDA to be acceptable and appropriate. The procedure and location of testing may depend on the nature of the emerging virus.
(ii) Within 60 days from the date that FDA notifies manufacturers that characterized viral samples are available for test evaluation and continuing until 3 years from that date, the results of the influenza emergency analytical reactivity testing, including the detailed information for the virus tested as described in the certificate of authentication, must be included as part of the device's labeling in a tabular format, either by:
(A) Placing the results directly in the device's § 809.10(b) of this chapter compliant labeling that physically accompanies the device in a separate section of the labeling where analytical reactivity testing data can be found, but separate from the annual analytical reactivity testing results; or
(B) In a section of the device's label or in other labeling that physically accompanies the device, prominently providing a hyperlink to the manufacturer's public Web site where the analytical reactivity testing data can be found. The manufacturer's home page, as well as the primary part of the manufacturer's Web site that discusses the device, must provide a prominently placed hyperlink to the Web page containing this information and must allow unrestricted viewing access.